PMID- 35344080
OWN - NLM
STAT- MEDLINE
DCOM- 20230307
LR  - 20230307
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 149
IP  - 3
DP  - 2023 Mar
TI  - Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean 
      patients with metastatic colorectal cancer who received oxaliplatin-containing 
      regimen.
PG  - 1131-1143
LID - 10.1007/s00432-022-03946-x [doi]
AB  - PURPOSE: To evaluate the safety and effectiveness of aflibercept in combination 
      with fluorouracil, leucovorin, and irinotecan (FOLFIRI) in Korean patients with 
      metastatic colorectal cancer (mCRC) who progressed with oxaliplatin-containing 
      regimen. METHODS: This was a prospective observational study conducted at 22 
      sites across Korea between February 2018 and September 2019. Patients 
      aged > 19 years with a diagnosis of mCRC who were prescribed aflibercept plus 
      FOLFIRI, after progression with an oxaliplatin-containing regimen were included. 
      Disease assessment was performed every 6 weeks. RESULTS: A total of 185 patients 
      were included (males, 58.9%; right-sided tumors, 23.8%; and ECOG performance 
      factor >/= 1, 68.6%). A total of 514 adverse events (AEs) occurred in 134 patients, 
      of which 206 (49.2%; 95% CI 42.0%, 56.4%) events were considered as adverse drug 
      reactions (ADRs), 172 unexpected AEs (49.7%; 95% CI 42.5%, 56.9%), and 53 serious 
      AEs (22.2%; 95% CI16.2%, 28.2%). The most common serious ADR was pneumonia 
      (n = 2, 1.6%). The most common all grade hematological AE and non-hematological 
      AE were neutropenia (21.6%) and nausea (16.2%), respectively. Over a median 
      follow-up of 5.6 months, a total of five grade 5 (1.0%) AEs were reported. Median 
      OS was 9.4 months, and median progression-free survival (PFS) was 7.3 months. The 
      overall response rate was 14.6%. Right-sided tumor location and prior bevacizumab 
      treatment were independent factors of poor PFS in multivariate analysis. 
      CONCLUSION: Aflibercept in combination with FOLFIRI was effective and showed an 
      acceptable safety profile in Korean patients with mCRC in daily clinical 
      practice.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Beom, Seung-Hoon
AU  - Beom SH
AD  - Division of Medical Oncology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
FAU - Kim, Jong Gwang
AU  - Kim JG
AUID- ORCID: 0000-0002-7615-5864
AD  - Department of Oncology/Hematology, Kyungpook National University Chilgok 
      Hospital, School of Medicine, Kyungpook National University, 807 Hoguk-ro, 
      Buk-gu, Daegu, 41404, Republic of Korea. jkk21c@knu.ac.kr.
FAU - Baik, Seung Hyuk
AU  - Baik SH
AD  - Section of Colon and Rectal Surgery, Department of Surgery, Yonsei University 
      College of Medicine, Gangnam Severance Hospital, 211 Eonju-Ro, Gangnam-Gu, Seoul, 
      South Korea.
FAU - Shin, Seong Hoon
AU  - Shin SH
AD  - Department of Internal Medicine, Kosin University Gospel Hospital, Busan, 
      Republic of Korea.
FAU - Park, Inkeun
AU  - Park I
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Gachon 
      University Gil Medical Center, 774-21 Namdongdero, Namdong-Gu, Incheon, Republic 
      of Korea.
FAU - Park, Young Suk
AU  - Park YS
AD  - Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 
      Republic of Korea.
FAU - Lee, Myung-Ah
AU  - Lee MA
AD  - Division of Medical Oncology, Department of Internal Medicine, Cancer Research 
      Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic 
      University of Korea, Seoul, Republic of Korea.
FAU - Lee, Soohyeon
AU  - Lee S
AD  - Division of Oncology/Hematology, Department of Internal Medicine, Korea 
      University Anam Hospital, 73 Goryeodae-ro Seongbuk-gu, Seoul, 02841, South Korea.
FAU - Jeon, So-Yeon
AU  - Jeon SY
AD  - Department of Internal Medicine, Jeonbuk National University Medical School, 
      Jeonju, Korea.
FAU - Han, Sae-Won
AU  - Han SW
AD  - Department of Internal Medicine, Seoul National University Hospital and Seoul 
      National University Cancer Research Institute, Seoul, Republic of Korea.
FAU - Kang, Myoung Hee
AU  - Kang MH
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang 
      National University Changwon Hospital, Gyeongsang National University College of 
      Medicine, Samjeongja-ro 11, Changwon, Republic of Korea.
FAU - Oh, Jisu
AU  - Oh J
AD  - Division of Medical Oncology, Department of Internal Medicine, Yongin Severance 
      Hospital, Yongin-si, Gyeonggi-do, Republic of Korea.
FAU - Kim, Jin Soo
AU  - Kim JS
AD  - Department of Surgery, Chungnam National University College of Medicine, Chungnam 
      National University Sejong Hospital, Sejong, Republic of Korea.
FAU - Kim, Jin Young
AU  - Kim JY
AD  - Division of Hematology and Oncology, Department of Internal Medicine, Keimyung 
      University Dongsan Hospital, Dalgubeol-daero, Dalseo-gu, Daegu, Republic of 
      Korea.
FAU - Ahn, Mi Sun
AU  - Ahn MS
AD  - Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, 
      16499, Republic of Korea.
FAU - Zang, Dae Young
AU  - Zang DY
AD  - Department of Internal Medicine, Hallym University Medical Center, Hallym 
      University College of Medicine, Anyang-si, Republic of Korea.
FAU - Bae, Byung-Noe
AU  - Bae BN
AD  - Department of Surgery, Inje University Sanggye Paik Hospital, Inje University 
      College of Medicine, 1342 Dongil-ro, Seoul, Republic of Korea.
FAU - Jo, Hong Jae
AU  - Jo HJ
AD  - Department of Surgery, Pusan National University School of Medicine, Pusan 
      National University Hospital, Busan, Republic of Korea.
FAU - Kim, Hee Kyung
AU  - Kim HK
AD  - Division of Oncology, Department of Internal Medicine, Chungbuk National 
      University Hospital, Chungbuk National University College of Medicine, Cheongju, 
      Republic of Korea.
FAU - Kim, Jung-Han
AU  - Kim JH
AD  - Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University 
      College of Medicine, Seoul, Republic of Korea.
FAU - Yoon, Ji Ae
AU  - Yoon JA
AD  - Medical Affairs of Oncology, Sanofi Korea, Seoul, Republic of Korea.
FAU - Kim, Dong Han
AU  - Kim DH
AD  - Medical Affairs of Oncology, Sanofi Korea, Seoul, Republic of Korea.
AD  - GSK Korea, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220327
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 15C2VL427D (aflibercept)
RN  - 04ZR38536J (Oxaliplatin)
RN  - XT3Z54Z28A (Camptothecin)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - U3P01618RT (Fluorouracil)
RN  - Q573I9DVLP (Leucovorin)
SB  - IM
MH  - Male
MH  - Humans
MH  - Oxaliplatin/therapeutic use
MH  - *Colorectal Neoplasms/pathology
MH  - Camptothecin/therapeutic use
MH  - *Colonic Neoplasms/drug therapy
MH  - Bevacizumab/therapeutic use
MH  - *Rectal Neoplasms/drug therapy
MH  - Fluorouracil/therapeutic use
MH  - Leucovorin/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Republic of Korea
OTO - NOTNLM
OT  - Acquired resistance
OT  - Anti-VEGF agents
OT  - Chemotherapy
OT  - Colorectal cancer
EDAT- 2022/03/29 06:00
MHDA- 2023/03/08 06:00
CRDT- 2022/03/28 12:16
PHST- 2021/08/12 00:00 [received]
PHST- 2022/02/04 00:00 [accepted]
PHST- 2022/03/29 06:00 [pubmed]
PHST- 2023/03/08 06:00 [medline]
PHST- 2022/03/28 12:16 [entrez]
AID - 10.1007/s00432-022-03946-x [pii]
AID - 10.1007/s00432-022-03946-x [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2023 Mar;149(3):1131-1143. doi: 
      10.1007/s00432-022-03946-x. Epub 2022 Mar 27.